Philogen company profile
Company profile
Philogen has 230 employees and is headquartered in Sovicille, Italy.
Philogen reported revenue of 319.7 million euros in the fiscal year ended 31 December 2025, and its work centres on drugs for cancer and chronic inflammatory conditions. Nidlegy is in Phase III testing for advanced melanoma and Fibromun in Phase III for soft-tissue sarcoma, while Darleukin, Dekavil and Dodekin are in earlier-stage trials for lung cancer, chronic inflammatory disorders and various solid tumors. A second line of small molecules, including OncoFAP, OncoACP3 and OncoCAIX, targets solid tumors, prostate cancer and renal cell carcinoma. The company operates in Italy, Switzerland, the United States and the European Union.
The group posted a net profit of 229.7 million euros in the same fiscal year, and it employs 230 people. Founded in 1996, it is headquartered in Sovicille, Italy.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Italy
- Headquarters
- Via Bellaria, 35, 53018, Sovicille
- Employees
- 230
- Chief executive
- Dario Neri
- Founded
- 1996
- Fiscal year
- January - December
- Listing
- PHIL · Borsa Italiana
- Currency
- EUR
- ISIN
- IT0005373789
- Website
- philogen.com
Philogen and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| PhilogenPHIL | Italy | $905.96M | 230 | 79.1% | 3.67 |
| InventivaIVA | France | $890.8M | 87 | -5,980.9% | — |
| Pharming GroupPHARM | Netherlands | $841.25M | 407 | 12.8% | 36.1 |
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
| Pharma MarPHM | Spain | $1.1B | 505 | 21.3% | 14.7 |
| GubraGUBRA | Denmark | $730.02M | 330 | -73.1% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
